Vis enkel innførsel

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

dc.contributor.authorSeppälä, Elina Marjukka
dc.contributor.authorVeneti, Lamprini
dc.contributor.authorStarrfelt, Jostein
dc.contributor.authorDanielsen, Anders Skyrud
dc.contributor.authorBragstad, Karoline
dc.contributor.authorHungnes, Olav
dc.contributor.authorTaxt, Arne Michael
dc.contributor.authorWatle, Sara Sofie Viksmoen
dc.contributor.authorMeijerink, Hinta
dc.date.accessioned2021-12-08T07:14:43Z
dc.date.available2021-12-08T07:14:43Z
dc.date.created2021-12-06T11:24:40Z
dc.date.issued2021
dc.identifier.citationEurosurveillance. 2021, 26 (35), 1-6.
dc.identifier.issn1025-496X
dc.identifier.urihttps://hdl.handle.net/11250/2833247
dc.language.isoeng
dc.titleVaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersion
dc.source.pagenumber1-6
dc.source.volume26
dc.source.journalEurosurveillance
dc.source.issue35
dc.identifier.doi10.2807/1560-7917.ES.2021.26.35.2100793
dc.identifier.cristin1964988
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail
Filnavn:
Seppala_2021_Vac.pdf
Størrelse:
169.8Kb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel